Jindal Supreme India Limited has refiled its IPO draft papers with the Securities and Exchange Board of India (SEBI) on April 13, 2026. The company had previously submitted the Draft Red Herring Prospectus (DRHP) last year on December 09, 2025.
As per the latest DRHP, Jindal Supreme IPO will be a book-building issue consisting of both a fresh issue of 1.07 crore equity shares and an offer for sale (OFS) component of 0.27 crore equity shares by promoter VVJ Enterprise Private Limited (previously known as J J Jindal Infin Private Limited).
Jindal Supreme India Limited is a leading manufacturer and supplier of steel pipes and tubes, catering to the needs of multiple infrastructure and industrial applications. Its product portfolio includes mild steel black pipes, galvanised pipes, tubes, metal beam crash barriers, and galvanised iron tubular poles.
Explore other Upcoming IPOs on BSE and NSE.
The Company proposes to utilise the Net Proceeds from the fresh issue towards:
Check out newly Listed IPOs on BSE and NSE.
Jindal Supreme (India) Limited is a Haryana-based steel products manufacturer incorporated in 1974, engaged in the production and supply of steel pipes, tubes, and related infrastructure products. Its portfolio includes MS black pipes, galvanised pipes, hollow sections, metal beam crash barriers, and GI tubular poles, which are used across sectors such as water supply, construction, roads and highways, oil & gas, agriculture, and rural electrification. The company operates an integrated manufacturing facility in Hisar, supported by a growing dealer network and direct institutional sales, catering to both government and private sector infrastructure projects across multiple states.
Financially, Jindal Supreme (India) Limited has demonstrated steady scale with improving profitability. The company reported total income of ₹586.40 crore in FY2025, with a profit after tax (PAT) of ₹11.16 crore, compared to ₹10.65 crore in FY2024.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.